Results 261 to 270 of about 36,481 (278)

Novel Modulators of CD39 and CD73

CD39 and CD73 are crucial in purinergic signalling, converting triphosphate and diphosphate nucleotides such as ATP and ADP into AMP, which CD73 further degrades into adenosine. CD39 and CD73 dysregulation is linked to various diseases. In cancer, their upregulation is associated with immune suppression, while downregulation in autoimmune disorders ...
openaire   +1 more source

Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer

European Journal of Cancer, 2021
Yun Gu, Hanji Fang, Yuchao Fei
exaly  

CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms

Cancer Letters, 2021
Xiaozhou Yu, Chongbiao Huang, Tiansuo Zhao   +2 more
exaly  

CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer

Journal of Cellular and Molecular Medicine, 2020
Qiangda Chen, Ning Pu, Hanlin Yin
exaly  

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

Cancer Cell, 2016
Arabella Young, Shin Foong Ngiow, Deborah S Barkauskas   +2 more
exaly  

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

Annals of Oncology, 2018
Laurence Buisseret, B Allard, S Garaud   +2 more
exaly  

CD73

2011
openaire   +1 more source

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

Journal of Surgical Oncology, 2012
Xiao-Sheng He, Yu-Feng Chen, Lei Lian
exaly  

CD73

2008
openaire   +1 more source

Anti‐CD73 therapy impairs tumor angiogenesis

International Journal of Cancer, 2014
Bertrand Allard, Isabelle Royal, John Stagg   +2 more
exaly